For Early Treatment of Mild COVID-19, University of Minnesota Trial Shows Hydroxychloroquine Has No Benefit Over Placebo
July 17, 2020
July 17, 2020
MINNEAPOLIS, Minnesota, July 17 -- The University of Minnesota issued the following news release on July 16:
University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the early treatment of mild COVID-19 among persons who are not hospitalized.
The trial results, published in the Annals of Internal Medicine, determined that hydroxychloroquine did not decrease the severity of COVID-19 . . .
University of Minnesota Medical School researchers published the results from the first randomized clinical trial testing hydroxychloroquine for the early treatment of mild COVID-19 among persons who are not hospitalized.
The trial results, published in the Annals of Internal Medicine, determined that hydroxychloroquine did not decrease the severity of COVID-19 . . .